Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02440685 · OUTCOME

Objective Response Rate

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors · Source last updated 2023-06-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
First 29 days

What was measured

Due to the early termination of the study, data for efficacy endpoints were insufficient for the planned efficacy analyses.

Groups in this outcome

10 mg BID

ASN002 10 mg BID

20 mg BID

ASN002 20 mg BID

30 mg BID

ASN002 30 mg BID

40 mg BID

ASN002 40 mg BID

50 mg BID

ASN002 50 mg BID

75 mg BID

ASN002 75 mg BID

100 mg BID

ASN002 100 mg BID

80 mg QD

ASN002 80 mg QD

120 mg QD

ASN002 120 mg QD

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
10 mg BID3
20 mg BID4
30 mg BID3
40 mg BID4
50 mg BID7
75 mg BID15
100 mg BID5
80 mg QD7
120 mg QD3

Reported measurements

Source class 1

Not evaluable

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
10 mg BID0Not reportedNot reportedNot reportedNot reported
20 mg BID1Not reportedNot reportedNot reportedNot reported
30 mg BID0Not reportedNot reportedNot reportedNot reported
40 mg BID2Not reportedNot reportedNot reportedNot reported
50 mg BID2Not reportedNot reportedNot reportedNot reported
75 mg BID12Not reportedNot reportedNot reportedNot reported
100 mg BID3Not reportedNot reportedNot reportedNot reported
80 mg QD1Not reportedNot reportedNot reportedNot reported
120 mg QD0Not reportedNot reportedNot reportedNot reported

Complete response

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
10 mg BID0Not reportedNot reportedNot reportedNot reported
20 mg BID0Not reportedNot reportedNot reportedNot reported
30 mg BID0Not reportedNot reportedNot reportedNot reported
40 mg BID0Not reportedNot reportedNot reportedNot reported
50 mg BID0Not reportedNot reportedNot reportedNot reported
75 mg BID0Not reportedNot reportedNot reportedNot reported
100 mg BID0Not reportedNot reportedNot reportedNot reported
80 mg QD0Not reportedNot reportedNot reportedNot reported
120 mg QD0Not reportedNot reportedNot reportedNot reported

Partial response

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
10 mg BID0Not reportedNot reportedNot reportedNot reported
20 mg BID0Not reportedNot reportedNot reportedNot reported
30 mg BID0Not reportedNot reportedNot reportedNot reported
40 mg BID0Not reportedNot reportedNot reportedNot reported
50 mg BID0Not reportedNot reportedNot reportedNot reported
75 mg BID1Not reportedNot reportedNot reportedNot reported
100 mg BID0Not reportedNot reportedNot reportedNot reported
80 mg QD0Not reportedNot reportedNot reportedNot reported
120 mg QD1Not reportedNot reportedNot reportedNot reported

Stable disease

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
10 mg BID0Not reportedNot reportedNot reportedNot reported
20 mg BID2Not reportedNot reportedNot reportedNot reported
30 mg BID1Not reportedNot reportedNot reportedNot reported
40 mg BID0Not reportedNot reportedNot reportedNot reported
50 mg BID1Not reportedNot reportedNot reportedNot reported
75 mg BID1Not reportedNot reportedNot reportedNot reported
100 mg BID0Not reportedNot reportedNot reportedNot reported
80 mg QD2Not reportedNot reportedNot reportedNot reported
120 mg QD1Not reportedNot reportedNot reportedNot reported

Progressive disease

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
10 mg BID3Not reportedNot reportedNot reportedNot reported
20 mg BID1Not reportedNot reportedNot reportedNot reported
30 mg BID2Not reportedNot reportedNot reportedNot reported
40 mg BID2Not reportedNot reportedNot reportedNot reported
50 mg BID4Not reportedNot reportedNot reportedNot reported
75 mg BID1Not reportedNot reportedNot reportedNot reported
100 mg BID2Not reportedNot reportedNot reportedNot reported
80 mg QD4Not reportedNot reportedNot reportedNot reported
120 mg QD1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        1
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        2
      5. group Id
        OG004
        value
        2
      6. group Id
        OG005
        value
        12
      7. group Id
        OG006
        value
        3
      8. group Id
        OG007
        value
        1
      9. group Id
        OG008
        value
        0
      title
      Not evaluable
    2. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        0
      6. group Id
        OG005
        value
        0
      7. group Id
        OG006
        value
        0
      8. group Id
        OG007
        value
        0
      9. group Id
        OG008
        value
        0
      title
      Complete response
    3. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        0
      6. group Id
        OG005
        value
        1
      7. group Id
        OG006
        value
        0
      8. group Id
        OG007
        value
        0
      9. group Id
        OG008
        value
        1
      title
      Partial response
    4. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        2
      3. group Id
        OG002
        value
        1
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        1
      6. group Id
        OG005
        value
        1
      7. group Id
        OG006
        value
        0
      8. group Id
        OG007
        value
        2
      9. group Id
        OG008
        value
        1
      title
      Stable disease
    5. measurements
      1. group Id
        OG000
        value
        3
      2. group Id
        OG001
        value
        1
      3. group Id
        OG002
        value
        2
      4. group Id
        OG003
        value
        2
      5. group Id
        OG004
        value
        4
      6. group Id
        OG005
        value
        1
      7. group Id
        OG006
        value
        2
      8. group Id
        OG007
        value
        4
      9. group Id
        OG008
        value
        1
      title
      Progressive disease
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      4
    3. group Id
      OG002
      value
      3
    4. group Id
      OG003
      value
      4
    5. group Id
      OG004
      value
      7
    6. group Id
      OG005
      value
      15
    7. group Id
      OG006
      value
      5
    8. group Id
      OG007
      value
      7
    9. group Id
      OG008
      value
      3
    units
    Participants
description
Due to the early termination of the study, data for efficacy endpoints were insufficient for the planned efficacy analyses.
groups
  1. description
    ASN002 10 mg BID
    id
    OG000
    title
    10 mg BID
  2. description
    ASN002 20 mg BID
    id
    OG001
    title
    20 mg BID
  3. description
    ASN002 30 mg BID
    id
    OG002
    title
    30 mg BID
  4. description
    ASN002 40 mg BID
    id
    OG003
    title
    40 mg BID
  5. description
    ASN002 50 mg BID
    id
    OG004
    title
    50 mg BID
  6. description
    ASN002 75 mg BID
    id
    OG005
    title
    75 mg BID
  7. description
    ASN002 100 mg BID
    id
    OG006
    title
    100 mg BID
  8. description
    ASN002 80 mg QD
    id
    OG007
    title
    80 mg QD
  9. description
    ASN002 120 mg QD
    id
    OG008
    title
    120 mg QD
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
First 29 days
title
Objective Response Rate
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice